England eliminates prescription copay for cancer patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Cancer patients in England will no longer have to pay prescription charges for medicines that treat their side effects, starting in April. Drugs that will be exempt include those that address pain, nausea, chronic diarrhea, fatigue, and mouth ulcers. Tamoxifen and other long-term hormone treatments are also currently subject to this charge.

Cancer patients in England will no longer have to pay prescription charges for medicines that treat their side effects, starting in April. Drugs that will be exempt include those that address pain, nausea, chronic diarrhea, fatigue, and mouth ulcers. Tamoxifen and other long-term hormone treatments are also currently subject to this charge.

Most medicines prescribed outside of hospitals by National Health Service (NHS) doctors are subject to a fixed charge of £7.10 (about $10.00) per item. Currently, patients being treated under the auspices of the NHS pay nothing for intravenous or oral chemotherapy drugs, analgesics, or antiemetics that are used during therapy sessions.

Cancer patients in England only (not the UK in general) can apply for a certificate that will exempt them from paying charges for prescription drugs for five years. They will remain eligible for free prescriptions even if they get the “all clear” before the five-year period is up. Th e exemption certificate can be renewed as many times as necessary, and it can be used when collecting any medicine prescribed by a general physician.

Up to 150,000 people already diagnosed with cancer stand to benefit from the scheme at an estimated cost to the NHS of £15 million ($21.5 million).

Government officials want to balance this loss of revenue by making greater use of generic products and by bulk-buying drugs more often.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content